SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-240034
Filing Date
2024-10-21
Accepted
2024-10-21 07:45:31
Documents
15
Period of Report
2024-10-17
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d881100d8k.htm   iXBRL 8-K 29367
2 EX-99.1 d881100dex991.htm EX-99.1 8106
6 GRAPHIC g881100snap1.jpg GRAPHIC 8106
  Complete submission text file 0001193125-24-240034.txt   180088

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fnch-20241017.xsd EX-101.SCH 2870
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fnch-20241017_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fnch-20241017_pre.xml EX-101.PRE 11721
18 EXTRACTED XBRL INSTANCE DOCUMENT d881100d8k_htm.xml XML 3804
Mailing Address 75 STATE STREET SUITE 100 BOSTON MA 02109
Business Address 75 STATE STREET SUITE 100 BOSTON MA 02109 617-229-6499
Finch Therapeutics Group, Inc. (Filer) CIK: 0001733257 (see all company filings)

IRS No.: 823433558 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40227 | Film No.: 241381972
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)